FDA delays decision, again, on KV's preterm birth drug
This article was originally published in Scrip
Executive Summary
The US FDA has delayed by three months its decision on the approval of Gestiva (hydroxyprogesterone caproate injection), which is under investigation by KV Pharmaceutical and its partner Hologic as therapy to prevent preterm birth in women with a singleton pregnancy who have a history of spontaneous preterm birth.